Turnaround times
The quoted turnaround time is from sample receipt in the laboratory, to results authorisation in the Laboratory Information Management system. The times do not include transport of specimen to the laboratory or the administrative process to print and post/email reports. Service users must allow for transport and reporting time when ordering tests.
Clinical background:
PYD and DPD are normally excreted in the urine, and larger quantities are excreted when bone resorption is increased. In contrast, when bone resorption is inhibited by bisphosphonates, oestrogen, or calcitonin therapy, the excretion of PYD and DPD is decreased. All available data indicate that PYD and DPD derive only from bone matrix degradation and thus are markers of bone resorption, not bone formation.
The assay for pyridinoline collagen cross-links is useful as a sensitive and specific marker in the diagnosis and management of bone loss in osteoporosis. The cross-links assay is also useful in measuring bone resorption in other metabolic bone diseases such as primary hyperparathyroidism and Paget’s disease.
Specimen container paediatric:
Plain universal container (random urine sample)
Specimen container adult:
Plain universal container (random urine sample)
Minimum volume paediatric:
10 mL
Minimum volume adult:
10 mL
Special requirements:
Protect from UV light in a container or with foil.
There is a significant circadian rhythm with higher levels of excretion at night (as much as 50%). It is therefore recommended that a carefully monitored second void urine is collected.
A baseline pre-treatment measurement is required if assessing response to antiresorption therapy.
Sample stability:
Store sample at -20°C